"Nasopharyngeal Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the NASOPHARYNX.
| Descriptor ID |
D009303
|
| MeSH Number(s) |
C04.588.443.665.710.650 C07.550.350.650 C07.550.745.650 C09.647.710.650 C09.775.350.650 C09.775.549.650
|
| Concept/Terms |
Nasopharyngeal Neoplasms- Nasopharyngeal Neoplasms
- Nasopharyngeal Neoplasm
- Neoplasm, Nasopharyngeal
- Neoplasms, Nasopharyngeal
- Nasopharynx Neoplasms
- Nasopharynx Neoplasm
- Neoplasm, Nasopharynx
- Neoplasms, Nasopharynx
Cancer of Nasopharynx- Cancer of Nasopharynx
- Nasopharynx Cancers
- Nasopharyngeal Cancer
- Cancer, Nasopharyngeal
- Cancers, Nasopharyngeal
- Nasopharyngeal Cancers
- Nasopharynx Cancer
- Cancer, Nasopharynx
- Cancers, Nasopharynx
- Cancer of the Nasopharynx
|
Below are MeSH descriptors whose meaning is more general than "Nasopharyngeal Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Nasopharyngeal Neoplasms".
This graph shows the total number of publications written about "Nasopharyngeal Neoplasms" by people in this website by year, and whether "Nasopharyngeal Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 3 | 1 | 4 |
| 2016 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 3 | 4 |
| 2023 | 1 | 1 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nasopharyngeal Neoplasms" by people in Profiles.
-
Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Ann Oncol. 2024 Dec; 35(12):1181-1190.
-
Landmark-based auto-contouring of clinical target volumes for radiotherapy of nasopharyngeal cancer. J Appl Clin Med Phys. 2024 Sep; 25(9):e14474.
-
Planet of the apex. Surv Ophthalmol. 2024 May-Jun; 69(3):495-498.
-
Prevalence of pituitary hormone dysfunction following radiotherapy for sinonasal and nasopharyngeal malignancies. Head Neck. 2023 10; 45(10):2525-2532.
-
Children's Oncology Group's 2023 blueprint for research: Rare tumors. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30574.
-
Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial. JAMA Netw Open. 2023 06 01; 6(6):e2316094.
-
Systematic Review and Meta-analysis of the Association Between Radiation Therapy Treatment Volume and Patient Outcomes. Int J Radiat Oncol Biol Phys. 2023 Dec 01; 117(5):1063-1086.
-
Intercellular transfer of activated STING triggered by RAB22A-mediated non-canonical autophagy promotes antitumor immunity. Cell Res. 2022 12; 32(12):1086-1104.
-
Rare POLN mutations confer risk for familial nasopharyngeal carcinoma through weakened Epstein-Barr virus lytic replication. EBioMedicine. 2022 Oct; 84:104267.
-
Neutrophil-to-lymphocyte ratio trend: A novel prognostic predictor in patients with nasopharyngeal carcinoma receiving radiotherapy. Int J Biol Markers. 2022 Sep; 37(3):270-279.